Pfizer Inc. said Friday the Food and Drug Administration approved Geodon as a part of a combination maintenance treatment for bipolar disorder in adults.
The new approval covers use of Geodon as an adjunct to lithium or valproate.
The drug is already approved as a treatment for schizophrenia and bipolar disorder.
Shares of Pfizer rose 20 cents to $18.31 in afternoon trading.
Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Terms & Conditions.
Powered and implemented by Interactive Data Managed Solutions
